Must Asset Management’s MaxCyte MXCT Stock Holding History

Must Asset Management’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-27,027	Closed	-$188K	–	42
2022 Q1	$188K	Hold	27,027	–	–	0.09%	46
2021 Q4	$284K	Buy	+27,027	New	+$290K	0.15%	39

Other funds holding MXCT

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RGI

River Global Investors London, United Kingdom $515M AUM 24.86% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Must Asset Management's MXCT Position: Q2 2022 in Review

Must Asset Management sold out of MaxCyte (MXCT) in Q2 2022, closing a stake of 27,027 shares — an estimated $188K sold.

Must Asset Management first reported a position in MXCT in Q4 2021 and held it in 2 quarters. The position peaked at $284K in Q4 2021. 102 funds tracked by Wall St. Rank hold MXCT as of Q2 2022.

Must Asset Management reported no remaining MaxCyte position as of Q2 2022 after selling out during the quarter.
Must Asset Management sold 27,027 MaxCyte shares in Q2 2022, an estimated $188K.
Must Asset Management first reported a position in MaxCyte in Q4 2021 and held it in 2 quarters.
Must Asset Management's MaxCyte position peaked at $284K in Q4 2021.
102 funds tracked by Wall St. Rank held MaxCyte as of Q2 2022.

Based on Must Asset Management's 13F filing for Q2 2022, filed 10 Aug 2022.